Clinical Trial Search

Primary: Change From Baseline in Nasal Polyp Score (NPS) at Week 24 — 0.06; -1.08 Score on a scale — p=<0.0001

Primary: Change From Baseline in Nasal Polyp Score (NPS) at Week 24 — -0.31; -0.90 Score on a scale — p=0.0140

Primary: Change in Nasal Polyp Score — .9; .3 score on a scale

Primary: Change From Baseline in Total Endoscopic Nasal Polyps Score at Week 52 — 0.0; -1.0 Scores on a scale — p=<0.001

Primary: Change From Baseline in Nasal Polyp Score (NPS) to Week 16 — -0.87; -0.89; -0.49 score on a scale — p=0.2364

Primary: Sinonasal Outcome Test (SNOT 20) — 50.33; 53.14; 37 Score out of total 100

Primary: Mean Change From Baseline in Total Endoscopic Nasal Polyps (NP) Score at Week 52 - ITT Population Excluding Medipharma Managed Sites — -0.62; -0.19 Scores on a Scale…

Primary: Change From Baseline in Total Endoscopic Nasal Polyps (NP) Score at Week 52 (Centrally Read) — -0.6; 0.2 Scores on a Scale — p=<0.001

Primary: Objective (a) the Effect on Polypoid Mucosal Thickening in the Anterior Ethmoid and Maxillary Sinuses as Measured on Sinus CT Scan. — -8.9; 4.2 % Change

Primary: Change From Baseline to Week 16 in Sino-Nasal Outcome Test (SNOT) 22 Total Score — -18.1; -18.3 score on a scale — p=0.9499

Primary: Number of Participants Who Reported Primary Symptoms — 27; 27; 25; 24 Participants

Primary: Change From Baseline at Week 16 in Sinonasal Outcome Test -22 (SNOT-22) Score — -14.09; -4.37 points

Primary: Change From Baseline in Bilateral Endoscopic Nasal Polyp Score (NPS) at Week 16 — 5.67; 5.87; 5.39; 3.97 score on a scale — p=0.0009

Primary: Change From Baseline in Symptoms as Measured by a Composite Score for Each Symptom of Nasal Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge (Anterior…

Primary: Change From Baseline in Total Endoscopic Nasal Polyps (NP) Score at Week 52 (Centrally Read) — -0.5; 0.1 Scores on scale — p=0.004

Primary: Change From Baseline to Week 24 in Opacification of Sinuses Assessed by Computed Tomography (CT) Scan Using the Lund Mackay (LMK) Score in Dupilumab Group — -6.63 Score…

Primary: Control Status of Patients With Rhinosinusitis — 19.5; 36.8; 43.7 percentage of participants

Primary: Sino-nasal Outcome Test (SNOT-22) Over Time — 43.8; 42.9; 39.7; 38.5 score on a scale — p=0.819

Primary: Change From Baseline in Total Nasal Polyp Score at Week 52 — -2.458; -0.380 Score — p=<.0001

Primary: Number of Participants With Nasal Polyp Plasma Cell Transcriptome — 10; 10; 10 Participants

Primary: Change in Sino-Nasal Outcome Test Scores (SNOT-22) — 23.18; 17.7 score on a scale

Primary: Ratio to Baseline in Peripheral Blood Eosinophil Counts After 6 Months of Treatment — 0.06 ratio to baseline — p=< 0.001

Primary: Change From Baseline in Symptoms as Measured by a Composite Score for Each Symptom of Nasal Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge (Anterior…

Primary: Change of Inflammation of the Nasal Mucosa and Paranasal Sinus — -2; -0.8 units on a scale

Primary: Change From Baseline to Week 24 in Nasal Polyp Score — -2.65; -1.05 score on a scale — p=<0.001

Primary: SNOT-22 Scores — 31.5; 10.29; 15.88 units on a scale

Primary: Number of Participants With a Reduced Need for Surgery at Week 25 — 16; 5; 33; 46 Participants — p=0.003

Primary: Change in Sino-nasal Outcome Test-22 Score Between Baseline and 6 Weeks, Then 6 Weeks to 12 Weeks. — 59.3; 52.9; 45.4; 51.8 units on a scale

Primary: Change From Baseline in Nasal Polyp Score (NPS) — -0.17; -0.85; -0.26; -1.06 Sore on a scale

Primary: Change From Baseline in Nasal Polyp Score at Week 16 — 0.20; -0.10; 0.14 score on scale — p=0.979